MedDeviceGuide — IVD & Medical Device Knowledge Base

How to design a PMCF survey under EU MDR that Notified Bodies accept as Level 4 clinical evidence — sample frame construction, inclusion/exclusion criteria, endpoint mapping to CER claims, acceptance criteria, statistical power, bias controls, adverse event capture, and when surveys alone are insufficient.

How to draft ISO 13485 / QMSR-compliant supplier quality agreements for critical outsourced vendors — cloud hosting providers, AI model/data vendors, penetration testing firms, ASCA/non-ASCA test labs, and sterilization vendors — with clause-by-clause guidance, vulnerability notification clauses, audit rights, CAPA cooperation, change notification, and evidence records.

Operational guide to converting an RUO-labeled assay or reagent into a cleared or approved IVD — covering marketing claims cleanup, distributor scripts, customer notices, historical data triage, validation bridge strategy, complaint transition, sales training, and evidence firewall construction.

Operational playbook for medical device PSIRT teams — SBOM component matching, exploitability analysis, VEX justification authoring, PSIRT severity scoring, CAPA trigger thresholds, field safety corrective action decisions, and customer communication timing.

Decision tree for when a software or cybersecurity update can use Special 510(k) vs Traditional 510(k) — risk analysis, V&V summary, FDA guidance, and evidence package requirements.

Practical playbook for responding to Notified Body deficiencies on SSCP documents under EU MDR — response table format, clinical benefit wording fixes, residual risk language, patient readability, CER/IFU alignment, translation consistency, and EUDAMED publication readiness.

2026 is the most consequential year for medical device UDI compliance globally. Mandatory deadlines hit in the EU (May 28), Switzerland (July 1), Australia (July 1), and China. This guide covers every active UDI system, class-by-class deadlines, data requirements, and what happens if you miss them.

The medical device CDMO market is projected to grow from $134.65 billion in 2025 to $354.60 billion by 2033 at 13.12% CAGR. This guide covers market size, growth drivers, key players (Jabil, Integer, Flex, Plexus), M&A trends, and how to choose the right contract manufacturing partner.

Switzerland's swissdamed database becomes mandatory on July 1, 2026, requiring all medical device manufacturers to register products and upload UDI data. This guide covers the Product Module, CH REP requirements, M2M functionality, grace period rules, immediate registration triggers, and the consequences of non-compliance.

Practical guide to the top 12 FDA cybersecurity deficiencies causing premarket submission holds in 2026 — SBOM gaps, threat modeling failures, risk assessment mistakes, and fixes aligned with the February 2026 final guidance and Section 524B.

How FDA and CDRH staffing cuts are affecting 510(k) review times, pre-submission meetings, and regulatory strategy — with data on CDRH capacity, MDUFA V performance, and practical mitigation strategies for device companies.

Complete guide to the GLP-1 drug-delivery device landscape in 2026 — auto-injector pens, oral delivery devices, combination product regulatory pathways, FDA and EU MDR requirements, and market outlook.

An analysis of the EU MDR and IVDR Notified Body capacity crisis using 2026 survey data — 33,175 MDR applications vs 17,549 certificates issued, 13–18 month review times, IVDR Class C deadline, and a practical action plan for manufacturers facing certification gaps.

A deep analysis of FDA's January 2025 draft guidance on AI-Enabled Device Software Functions — total product lifecycle approach, data management requirements, bias mitigation strategies, transparency expectations, marketing submission content, and practical steps manufacturers should take before the guidance is finalized.

A comprehensive guide to regulatory sandboxes for medical devices — MHRA AI Airlock (£3.6M expansion), FDA TEMPO pilot for digital health, EU sandbox proposals, and how manufacturers can participate in these programs to accelerate market access.

How the EU Corporate Sustainability Reporting Directive affects medical device manufacturers — scope, ESRS standards, double materiality, timelines, Omnibus simplification, and practical compliance steps for MedTech.

How to select, evaluate, and change Notified Bodies under EU MDR and IVDR — capacity constraints, selection criteria, transfer process, 2026 implementing regulation, and timeline planning.

How Good Clinical Practice applies to medical device clinical trials — navigating ISO 14155:2026 and ICH E6(R3), sponsor and investigator responsibilities, informed consent, safety reporting, and audit readiness.

An independent comparison of the top regulatory intelligence platforms for medical device and IVD manufacturers in 2026 — covering RegDesk, IQVIA, Cortellis, Obsidian, Basil Systems, ArisGlobal, Freyr RegIntel, and Veeva Vault Regulatory.

Protocol-level guide to cleaning validation for reusable surgical instruments — covering artificial soil selection, protein/hemoglobin/TOC endpoints, worst-case device families, manual vs automated cleaning, ANSI/AAMI ST98 acceptance criteria, sample size justification, and report structure.